June 26 (Reuters) - Acasti Pharma Inc ACST.V :
* ACASTI PHARMA PROVIDES FISCAL 2019 YEAR-END BUSINESS UPDATE
* ACASTI PHARMA INC - BOTH PHASE 3 TRILOGY STUDIES AT 100% RANDOMIZATION
* ACASTI PHARMA INC - HAD $34.4 MILLION OF CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF MARCH 31, 2019
* ACASTI PHARMA INC - REMAIN ON TRACK TO REPORT TOPLINE RESULTS FOR PRIMARY ENDPOINT OF LOWERING TRIGLYCERIDES FOR TRILOGY 1 IN DECEMBER 2019
* ACASTI PHARMA INC - MANAGEMENT BELIEVES CO IS SUFFICIENTLY CAPITALIZED BEYOND COMPLETION OF PHASE 3 TRIALS
* ACASTI PHARMA INC - REMAIN ON TRACK TO REPORT TOPLINE RESULTS FOR TRILOGY 2 IN JANUARY 2020.
* ACASTI PHARMA INC - THERE EXISTS A MATERIAL UNCERTAINTY ABOUT ACASTI'S ABILITY TO CONTINUE AS A GOING CONCERN.
* ACASTI PHARMA INC - WILL NEED TO RAISE ADDITIONAL CAPITAL IN FUTURE TO COMPLETE FUNDING OF ITS NDA PREPARATIONS AND US COMMERCIAL LAUNCH ACTIVITIES